VIR Oct 2024 10.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 01:57PM EDT
| Previous Close | 3.1000 |
| Open | 2.5500 |
| Bid | 2.2000 |
| Ask | 3.2000 |
| Strike | 10.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 2.4500 - 2.5500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 147 |
ZacksVir Biotechnology (VIR) Up on Positive Data From HDV Study
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
SAN FRANCISCO, June 05, 2024--New data from Vir Biotechnology reinforces the potential for a transformative treatment for hepatitis delta, the most severe form of viral hepatitis.
Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SAN FRANCISCO, May 29, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida.
© 2024 Yahoo. All rights reserved.